Annals of Oncology 12:349-352, 2001
© 2001 European Society for Medical Oncology
research-article |
CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma?
1Division of Hematology/Oncology, Department of Medicine, Sungkyunkwan University School of Medicine Kangnam-Ku, Seoul, Korea
2Radiation Oncology, Sungkyunkwan University School of Medicine Kangnam-Ku, Seoul, Korea
3Otorhinolaryngology, Sungkyunkwan University School of Medicine Kangnam-Ku, Seoul, Korea
4Diagnostic Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine Kangnam-Ku, Seoul, Korea
Correspondence to:K. Park, MD, PhD, Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 IIwon-Dong, Kangnam-Ku, Seoul 135-710, Korea, E-mail: kpark{at}smc.samsung.co.kr
The present study aimed to analyse the treatment outcome of four cycles of CHOP (cyclophosphamide—vincristine—doxorubicin—prednisolone) followed by involved field radiation therapy (IF RT) for the treatment of stage I–II nasal natural killer (NK)/T-cell lymphoma.
From March 1995 to December 1999, 17 patients (median age 41 years; range 30–66) with localized nasal NK/T-cell lymphoma were enrolled. B symptoms were noted in five patients (31%). Sixteen of seventeen patients (94%) were of low risk when classified according to the International Prognostic Index (IPI).
The treatment plan consisted of four cycles of CHOP/ chemotherapy followed by IF RT of 45 Gy. Two patients received radiation during the first or second cycle of CHOP because of bleeding from the primary tumour site. Both patients achieved complete responses (CRs). In the remaining 15 patients, after 4 cycles of CHOP, 6 CRs and 3 partial responses (PRs) were achieved (53% of response rate). IF RT was given to six patients (four in CR, one in PR and one in PD), and all six patients achieved CR. Overall, CR was achieved in 10 of 17 patients (58%). The planned sequential chemoradiotherapy was completed in only 6 of 17 patients (35%) because of the progression during chemotherapy. None of the patients who achieved CR experienced relapse of lymphoma during follow-up. The estimated overall three-year survival rate was 59%. In univariate analysis, B symptoms and stage were significant prognostic factors for response and overall survival (P < 0.05).
The present study suggests that four cycles of CHOP followed by IF RT is not satisfactory for treating patients with localized nasal NK/T-cell lymphoma, and that further exploration for improved therapy is needed.
chemotherapy, involved field radiation, nasal NK/T-cell lymphoma
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Yamaguchi, K. Tobinai, M. Oguchi, N. Ishizuka, Y. Kobayashi, Y. Isobe, K. Ishizawa, N. Maseki, K. Itoh, N. Usui, et al. Phase I/II Study of Concurrent Chemoradiotherapy for Localized Nasal Natural Killer/T-Cell Lymphoma: Japan Clinical Oncology Group Study JCOG0211 J. Clin. Oncol., November 20, 2009; 27(33): 5594 - 5600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Suzuki, J. Suzumiya, M. Yamaguchi, S. Nakamura, J. Kameoka, H. Kojima, M. Abe, T. Kinoshita, T. Yoshino, K. Iwatsuki, et al. Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type Ann. Onc., October 22, 2009; (2009) mdp418v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N TOMITA, T KODAIRA, H TACHIBANA, T NAKAMURA, R NAKAHARA, H INOKUCHI, N MIZOGUCHI, and A TAKADA A comparison of radiation treatment plans using IMRT with helical tomotherapy and 3D conformal radiotherapy for nasal natural killer/T-cell lymphoma Br. J. Radiol., September 1, 2009; 82(981): 756 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, B. Wang, X. Ma, and Y. Guo NF-{kappa}B Activation Through the Alternative Pathway Correlates with Chemoresistance and Poor Survival in Extranodal NK/T-cell Lymphoma, Nasal Type Jpn. J. Clin. Oncol., July 1, 2009; 39(7): 418 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-S. Kim, D.-W. Kim, S.-A. Im, C. W. Kim, T.-Y. Kim, S.-S. Yoon, D. S. Heo, Y.-J. Bang, S. Park, B. K. Kim, et al. Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone Ann. Onc., January 1, 2009; 20(1): 121 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Sandlund Clinical Features and Treatment Approaches for the Uncommon Non-Hodgkin Lymphoma Subtypes in Children ASCO Educational Book, January 1, 2009; 2009(1): 598 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lee, C. Suh, H. J. Kang, B.-Y. Ryoo, J. Huh, Y. H. Ko, H.-S. Eom, K. Kim, K. Park, and W. S. Kim Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma Ann. Onc., December 1, 2008; 19(12): 2079 - 2083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Suh, Y.-K. Kang, J.-L. Roh, M. R. Kim, J. S. Kim, J. Huh, J. H. Lee, Y. J. Jang, and B.-J. Lee Prognostic Value of Tumor 18F-FDG Uptake in Patients with Untreated Extranodal Natural Killer/T-Cell Lymphomas of the Head and Neck J. Nucl. Med., November 1, 2008; 49(11): 1783 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Kim, S. -Y. Lee, Y. K. Jeon, B. -Y. Ryoo, G. J. Cho, Y. S. Hong, H. J. Kim, S.-Y. Kim, C. S. Kim, S. Kim, et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group Ann. Onc., August 1, 2008; 19(8): 1477 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lee, C. Suh, J. Huh, H. J. Jun, K. Kim, C. Jung, K. Park, Y. H. Park, Y. H. Ko, and W. S. Kim Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type Clin. Cancer Res., June 1, 2007; 13(11): 3250 - 3254. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Pagano, A. Gallamini, G. Trape, L. Fianchi, D. Mattei, G. Todeschini, A. Spadea, S. Cinieri, E. Iannitto, M. Martelli, et al. NK/T-cell lymphomas 'nasal type': an Italian multicentric retrospective survey Ann. Onc., May 1, 2006; 17(5): 794 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lee, C. Suh, Y. H. Park, Y. H. Ko, S. M. Bang, J. H. Lee, D. H. Lee, J. Huh, S. Y. Oh, H.-C. Kwon, et al. Extranodal Natural Killer T-Cell Lymphoma, Nasal-Type: A Prognostic Model From a Retrospective Multicenter Study J. Clin. Oncol., February 1, 2006; 24(4): 612 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-X. Li, B. Yao, J. Jin, W.-H. Wang, Y.-P. Liu, Y.-W. Song, S.-L. Wang, X.-F. Liu, L.-Q. Zhou, X.-H. He, et al. Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma J. Clin. Oncol., January 1, 2006; 24(1): 181 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Kim, Y. H. Park, S.-Y. Lee, J.-H. Kim, D.-W. Kim, S.-A. Im, T.-Y. Kim, C. W. Kim, D. S. Heo, Y.-J. Bang, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type Blood, December 1, 2005; 106(12): 3785 - 3790. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kim, E. K. Chie, C. W. Kim, I. H. Kim, and C. I. Park Treatment Outcome of Angiocentric T-cell and NK/T-cell Lymphoma, Nasal Type: Radiotherapy Versus Chemoradiotherapy Jpn. J. Clin. Oncol., January 1, 2005; 35(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-Y. You, K.-H. Chi, M.-H. Yang, C.-C. Chen, C.-H. Ho, W.-K. Chau, H.-C. Hsu, J.-P. Gau, C.-H. Tzeng, J.-H. Liu, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan Ann. Onc., April 1, 2004; 15(4): 618 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-S. Chim, S.-Y. Ma, W.-Y. Au, C. Choy, A. K. W. Lie, R. Liang, C.-C. Yau, and Y.-L. Kwong Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index Blood, January 1, 2004; 103(1): 216 - 221. [Abstract] [Full Text] [PDF]
|
|